| Date | Title | | | Nov 05, 2009 | Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%| SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008. The Company had approximately $55.0 million in cash and cash equivalents as of September 30, 2009.
"While we have started t... |
|  | | Nov 02, 2009 | Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 5|
SEATTLE, Nov. 2 /PRNewswire-FirstCall/ -- On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2009 third quarter financial results.
Conference Call Numbers
Thursday, November 5
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-941-6010 (US Participants)
1-1-48... |
| | | Oct 29, 2009 | Cell Therapeutics, Inc.'s (CTI) Presentation at BIO Investor Forum to be Webcast|
SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 8th Annual Biotechnology Industry Organization (BIO) Investor Forum on Thursday, October 29 at 10:00 a.m. Pacific Time.
The conference is being held October 28-29, 2009, at the Palace Hotel in San Francisco. The presentation will be webcast live with slides and available for replay afterwards. The webcast can be accessed at www.celltherapeutics.com.
... |
| | | Oct 26, 2009 | Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum|
SEATTLE, Oct. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 8th Annual Biotechnology Industry Organization (BIO) Investor Forum. The conference will be held October 28-29, 2009, at the Palace Hotel in San Francisco. CTI will present on Thursday, October 29 at 10:00 a.m. Pacific Time. The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.cel... |
| | | Oct 22, 2009 | Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma| SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.
Highlights from the presentation includ... |
| | | Oct 21, 2009 | Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders|
SEATTLE, Oct. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today the results from its Annual Meeting of Shareholders held on Tuesday, October 20, 2009.
At the meeting, shareholders elected Mr. Richard L. Love, Dr. Mary O. Mundinger, and Dr. Jack W. Singer to serve on the Company's Board of Directors until the 2012 Annual Meeting. Shareholders approved the proposals to increase the number of shares available for iss... |
| | | Oct 16, 2009 | Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009|
SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- On Tuesday, October 20, 2009, at 1:00 PM Eastern Time/10:00 AM Pacific Time/7:00 PM Central European Time, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host an Annual Meeting of Shareholders at its Seattle headquarters, located at 501 Elliott Ave. West, Seattle, WA 98119. The meeting will also be webcast live on CTI's website at http://www.CellTherapeutics.com, and archived for replay.
... |
| | | Oct 01, 2009 | OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer| Phase II results to be presented at Proffered Session of International Society of Gastrointestinal Oncology
PHILADELPHIA, Oct. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pe... |
| | | Sep 29, 2009 | Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)|
SEATTLE, Sept. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL. CTI anticipates the formal Marketing Authorization Application (MAA) filing in 2010 following approval of the pediatric in... |
| | | Sep 28, 2009 | Cell Therapeutics Finalizes Asset Sale and Closure of Italian Branch, Saves $20 Million in 2010 Annual Operating Expenses|
SEATTLE, Sept. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has finalized the closing its Bresso, Italy operations and will receive approximately $1.1 million from the sale of assets. CTI expects the closure to save approximately $20 million in annual operating expenses in 2010 and beyond based on current exchange rates. The Bresso facility was used for pre-clinical research and was underutilized due to CTI's focused business m... |
| | | Sep 24, 2009 | OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting|
SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on... |
| | | Sep 22, 2009 | Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index|
SEATTLE, Sept. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
The NASDAQ OMX Global Biotechnology Index is a modified market-capitalization weighted index designed to track the performance of the largest and most liquid companies engaged in the biotechnology secto... |
| | | Sep 21, 2009 | Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis| CTI withdraws European Marketing Authorization Application (MAA) for non-inferiority indication in non-small cell lung cancer
SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the us... |
| | | Sep 16, 2009 | 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap| Update Also Demonstrates 3.3-month Improvement over Standard Chemotherapy in Median Overall Survival
SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to ... |
| | | Sep 16, 2009 | Cell Therapeutics, Inc.'s (CTI) Presentation at BioCentury NewsMakers Conference to be Webcast|
SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at BioCentury's NewsMakers in the Biotech Industry conference on Wednesday, September 16, 2009, at 10:30 AM Eastern.
The conference will be held September 16, 2009, at the Millennium Broadway Hotel in New York.
The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.
... |
| | | Sep 15, 2009 | Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)|
SEATTLE, Sept. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
"PIPs were introd... |
| | | Sep 10, 2009 | Cell Therapeutics, Inc. (CTI) to Present at BioCentury's NewsMakers in the Biotech Industry Conference|
SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at BioCentury's NewsMakers in the Biotech Industry conference on Wednesday, September 16, 2009, at 10:30 AM Eastern.
The conference will be held September 16, 2009, at the Millennium Broadway Hotel in New York. The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.
... |
| | | Sep 09, 2009 | Cell Therapeutics, Inc.'s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast|
SEATTLE, Sept. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9th at 11:40 AM Eastern in the Spellman Salon (5th Floor) at the New York Palace Hotel.
The conference will also be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.
Rodman & Renshaw 11th An... |
| | | Sep 05, 2009 | FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA|
SEATTLE, Sept. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). Pixantrone has fast track designation for the relapsed / refrac... |
| | | Sep 03, 2009 | Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference|
SEATTLE, Sept. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9th at 11:40 AM Eastern in the Spellman Salon (5th Floor) at the New York Palace Hotel.
The conference will also be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.
Rodman & Renshaw 11th ... |
| | | Aug 24, 2009 | FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone| FDA opts for standard review -- Cell Therapeutics to discuss merits for
priority review -- final decision due September 4th
SEATTLE, Aug. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug
Administration (FDA) has accepted and has filed for review the Company's New
Drug Application (NDA) for pixantrone as treatment for relapsed or refractory
aggressive non-Hodgkin's lymphoma (NHL). A Pres... |
| | | Aug 21, 2009 | Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants| SEATTLE, Aug. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq
and MTA: CTIC) (the "Company") today announced the closing of its previously
announced sale of $30 million of shares of its Series 2 Preferred Stock and
warrants to purchase shares of its common stock in a registered offering to a
single institutional investor. The investor has elected to convert all of its
shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the
Company's common stock iss... |
| | | Aug 19, 2009 | Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants| SEATTLE, Aug 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares o... |
| | | Aug 06, 2009 | Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval| Total Net Operating Expenses Decrease Significantly in First Half 2009
Compared to First Half 2008
SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today reported recent achievements and financial
results for the second quarter and six months ended June 30, 2009.
"The second quarter of 2009 was a transforming quarter for the Company as
we reported, in a peer reviewed setting, pixantrone phase III dat... |
| | | Aug 05, 2009 | Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6| SEATTLE, Aug 05, 2009 /PRNewswire-FirstCall via COMTEX/ -- On Thursday, August 6, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2009 second quarter financial results.
Conference Call Numbers
Thursday, August 6
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-941-9205 (US Participants)
1-... |
| | | Aug 03, 2009 | OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer| Encouraging progression-free survival in investigator sponsored trial results
published at 13th World Conference on Lung Cancer
SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced results from a study released by
Dartmouth-Hitchcock Medical Center at the International Association for the
Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. The study
demonstrated that in patients with advanced non-sma... |
| | | Jul 29, 2009 | Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe|
- European Medicines Agency (EMEA) notifies CTI that pixantrone is eligible
for centralized procedure in European Union
- CTI granted Small and Medium Enterprise (SME) status by the European Union
and EMEA - will provide additional development assistance and reduce cost for
regulatory filing
SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) announced today that it was notified by ... |
| | | Jul 28, 2009 | Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants| SEATTLE, July 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq
and MTA: CTIC) ("CTI" or the "Company") today announced the closing of its
previously announced public offering of 33,731,923 shares of its common stock
and warrants to purchase up to 8,432,981 shares of its common stock, including
the underwriter's exercise of its overallotment option. The Company received
approximately $40.3 million in net proceeds from the offering, after deducting
underwriting discounts and... |
| | | Jul 24, 2009 | Cell Therapeutics, Inc. Announces Exercise of Overallotment| SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq
and MTA: CTIC) ("CTI" or the "Company") today announced that the underwriter
of its previously announced public offering of 29,332,107 shares of its common
stock and warrants to purchase up to 7,333,027 shares of its common stock has
exercised in full its option to purchase 4,399,816 additional shares of its
common stock and warrants to purchase up to 1,099,954 additional shares of its
common stock to cover over... |
| | | Jul 23, 2009 | Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants| SEATTLE, July 23, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) ("CTI" or the "Company") today announced the pricing of an underwritten public offering of 29,332,107 shares of its common stock and warrants to purchase up to 7,333,027 shares of its common stock at a price to the public of $1.30 per share of common stock and warrant to purchase 0.25 shares of common stock, for gross proceeds of approximately $38.1 million. In connection with the offering... |
| | | Jul 22, 2009 | Cell Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants| SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq
and MTA: CTIC) ("CTI" or the "Company") today announced that it has commenced
an underwritten public offering of up to 29,332,107 shares of its common stock
and warrants to purchase up to 7,333,027 shares of its common stock. In
connection with the offering, the Company plans to grant the underwriter a
30-day option to purchase up to 4,399,816 additional shares of its common
stock and warrants to purchase up to... |
| | | Jul 21, 2009 | National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness| Results provide bio-marker for guiding brostallicin clinical trials in
patients with likely anti-tumor response
SEATTLE, July 21 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq
and MTA: CTIC) announced today that researchers from the Laboratory of
Molecular Pharmacology at the National Cancer Institute presented new
preclinical research identifying unique anti-tumor mechanisms of brostallicin
that sets this agent apart from other currently used ... |
| | | Jul 07, 2009 | European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application| Potential regulatory approval decision in Q4-2009
SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) announced today that it had requested and the EMEA has
agreed to an oral explanation in support of the OPAXIO Marketing Authorization
Application (MAA) in September, 2009 extending the review for the Committee
for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009.
In April, 2008 the EMEA accepted for rev... |
| | | Jun 30, 2009 | Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes| SEATTLE, June 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) announced today that it has been added to the Russell
3000(R), Russell 2000(R) and Russell Global(R) Indexes posted by Russell
Investments on June 29, 2009 on www.russell.com. Russell Investments
reconstitutes its family of U.S. and global equity indexes on an annual basis.
Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest
U.S. stocks as of the last trading da... |
| | | Jun 24, 2009 | Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review| Completed NDA submission could lead to marketing approval in Q4-2009
SEATTLE, June 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) announced today that it has completed the submission of
the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's
lymphoma (NHL). CTI requested priority review, which if granted could lead to
an approval decision from the FDA ... |
| | | Jun 22, 2009 | Responses After Completion of Therapy Increase Pixantrone CR/CRu Rate to 24% and ORR to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial| SEATTLE, June 22, 2009 /PRNewswire-FirstCall via COMTEX/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups
Additional Clinical Studies Also Highlighted at Pan Pacific Conference
-- Randomized phase III; PIX 302-Pixantrone plus rituximab significantly
improves CR rate (35% vs. 11%), ORR (75% vs. 33%) and time to
progression (TT... |
| | | Jun 19, 2009 | Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding| SEATTLE, June 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the
"Company" or "CTI") (Nasdaq and MTA: CTIC) today announced the final results
of its separate concurrent fixed price exchange offers (each, an "Exchange
Offer" and together, the "Exchange Offers") for any and all of the
approximately $118.9 million outstanding principal amount of five series of
its convertible notes (the "Notes"). The Exchange Offers expired at 5:00
p.m., New York City time, on Tuesday, June 16, 20... |
| | | Jun 17, 2009 | Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding|
SEATTLE, June 17 /PRNewswire-FirstCall/ --
-- Holders of Approximately 46.1% of Outstanding Notes Tendered in the
Exchange Offers
-- Outstanding Debt to be Reduced by Approximately $54.8 Million
-- Future Annual Interest Expense Reduced by Approximately $3.4 Million
-- Company to Book Approximately $8.2 Million Estimated Gain on Exchange
-- Shareholder's Equity to Increase by Approximately $45.4 Million
Cell Therapeutics, Inc. (the "Compa... |
| | | Jun 16, 2009 | Pixantrone Overview in Non-Hodgkin's Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference| SEATTLE, June 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of
Ottawa Hospital will be presenting an overview of pixantrone clinical studies
in non-Hodgkin's lymphoma at the 2009 Pan Pacific Lymphoma Conference on
Monday, June 22, 2009. The conference will be held from June 22-26, 2009 at
the Fairmont Orchid hotel on the Big Island of Hawaii.
2009 Pan Pacific Lymphoma Co... |
| | | Jun 15, 2009 | Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index| --Final Determination to be made on June 26, 2009
SEATTLE, June 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has been included on a list of preliminary additions to the Russell 3000(R) Index and Russell Global(R) Index posted by Russell Investments on June 12, 2009 on www.russell.com. Russell Investments will reconstitute its family of U.S. and global equity indexes on June 26, 2009.
"We are pleased to be on the... |
| | | Jun 10, 2009 | Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options| SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) announced today that a summary of the pixantrone Phase
III clinical data that were presented at American Society of Clinical Oncology
(ASCO) 2009 Annual Meeting on June 1, 2009 is now available at Clinical Care
Options website http://www.clinicaloptions.com. Clinical Care Options is an
independent medical education company that provides state-of-the-art medical
information to healthcare pr... |
| | | Jun 08, 2009 | Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL| Overview of 11 peer review publications presented in 'Future Oncology'
SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications
spanning preclinical, Phase I and Phase II clinical studies with pixantrone
was reviewed in the May 2009 edition of Future Oncology (Volume 5, Issue 4)
which is now available on line. The article, "Pixantrone: a promising drug in
the treatment of non-Hodgkin lymphomas,"... |
| | | Jun 03, 2009 | Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer| --Promising Preliminary Results on Radiation Sensitization from Phase II Trial May Serve as Additional Registration Direction for OPAXIO
ORLANDO, Fla., June 3, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that, in a study released from Brown University at the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting, patients with cancer of the lower esophagus had evidence of a high pathological complete response ("... |
| | | Jun 02, 2009 | Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes| SEATTLE, June 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the
"Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended
and restated its "Modified Dutch Auction" tender offer to a fixed price tender
offer for any and all of the approximately $118.9 million outstanding
principal amount of five series of its convertible notes (the "Notes"). In
addition, rather than a single offer for a combined aggregate principal amount
of Notes, the Company is now offerin... |
| | | Jun 02, 2009 | Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment| Panel Discussant Focuses on Longer Duration of Remission among Patients
Achieving a Complete Remission with Pixantrone than Complete Remissions
Achieved with Standard Chemotherapy
ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) announced today that at the poster and discussion
session of the Lymphoma and Plasma Cell Disorders Section at the 2009 American
Society of Clinical Oncology ("ASCO") Annual Meeting, new subgroup analysis
data wer... |
| | | Jun 01, 2009 | Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma| First Randomized Trial to Demonstrate Superior Clinical Benefit in
Relapsed/Refractory Aggressive NHL
ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ --
Intent to treat Analysis results per FDA agreed upon Statistical Analysis
Plan
Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021
Significant Increase in Overall Response Rate 37.1% vs. 14.3%; p=0.003
Significant increase in percent of all patients whose response lasted
greater tha... |
| | | May 19, 2009 | Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial| --Updated Safety data presented at BIO International Convention in
ATLANTA, May 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Updated Safety data presented at BIO International Convention in Atlanta
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs ... |
| | | May 18, 2009 | Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes| SEATTLE, May 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended its "Modified Dutch Auction" tender offer (the "Exchange Offer") to increase the total consideration of its offer to exchange shares of its common stock, no par value (the "Common Stock"), and cash for an aggregate of up to $89.2 million principal amount of the following outstanding series of its convertible notes (the "Notes"):
... |
| | | May 15, 2009 | Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting| SEATTLE, May 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced that data from CTI's pivotal phase III EXTEND
(PIX301) trial of pixantrone in patients with advanced, relapsed aggressive
non-Hodgkin's lymphoma (NHL) will be presented at the 2009 American Society of
Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to
June 2, 2009 in Orlando, Florida.
Ruth Pettengell, M.D. of St. George's Hospital, University of London, a... |
| | | May 15, 2009 | Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses|
--Reaches severance agreement with unions
SEATTLE, May 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that, as previously discussed in a press release on February 27, 2009, it is closing its Bresso, Italy operations and has reached agreement with the employee union on a severance package. The agreement relates to a reduction of CTI's total headcount in Italy by 56 positions in the immediate months, and is expected to sav... |
| | | May 14, 2009 | Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention| SEATTLE, May 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 2009 BIO International Convention at the Georgia International Convention Center in Atlanta, Georgia, on Tuesday, May 19th at 10:40 AM in Room 311 of Building A, Level 3.
2009 BIO International Convention
CTI Presentation: Tuesday, May 19, 2009
10:40 AM Eastern/4:40 PM Central European/7... |
| | | May 12, 2009 | Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer| SEATTLE, May 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI")
(Nasdaq and MTA: CTIC) today announced that it has commenced a "Modified Dutch
Auction" tender offer (the "Exchange Offer") to exchange shares of its common
stock, no par value ("Common Stock"), and cash for an aggregate of $89.2
million principal amount for the following outstanding series of Convertible
Notes (the "Notes"):
-- 4% Convertible Senior Subordinated Notes due 2010
-- 5.75% Convertible S... |
| | | May 11, 2009 | Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $20 Million of Common Stock and Warrants| SEATTLE, May 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq
and MTA: CTIC) (the "Company") today announced that it has sold $20 million
of shares of common stock at $1.25 per share and warrants to purchase shares
of common stock in a registered offering to a single institutional investor.
The Company currently expects to utilize up to $17.8 million in cash currently
on hand and/or cash received in connection with this offering to pay for its
anticipated tender offer to r... |
| | | May 11, 2009 | Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer| SEATTLE, May 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq and MTA: CTIC) today announced that that its Board
of Directors has authorized a "Modified Dutch Auction" tender offer (the
"Exchange Offer") and that it intends to exchange shares of its common stock,
no par value ("Common Stock"), and cash for up to approximately an aggregate
of $89.2 million principal amount for the following outstanding shares of the
Company's convertible notes (the "... |
| | | May 07, 2009 | Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009| Pixantrone Named-Patient Program Initiated in Europe
SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) reported recent accomplishments and financial results
for the quarter ended March 31, 2009.
"Our focus for the first half of 2009 was to initiate and complete the NDA
submission for pixantrone while we implemented final steps in our cost cutting
efforts and raised much needed operating capital on the least dilutive terms
possible --... |
| | | May 05, 2009 | Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7| SEATTLE, May 5 /PRNewswire-FirstCall/ -- On Thursday, May 7, 2009, at 8:30
a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell
Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a
conference call to discuss the Company's 2009 first quarter achievements and
financial results.
Conference Call Numbers
Thursday, May 7
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-888-561-1799 (US ... |
| | | May 05, 2009 | Pixantrone Now Available in Europe on a Named-Patient Basis| --Cell Therapeutics and IDIS Partner to Accelerate Patient Access to Pixantrone through Program
SEATTLE, May 5, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is... |
| | | Apr 21, 2009 | Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin| Identifies potential clinical trial strategies for personalized approach
to cancer treatment
SEATTLE, April 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a
wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA:
CTIC), presented data from a preclinical study, which utilized RNA
interference (RNAi) and bioinformatics to identify genetic markers - "contexts
of vulnerability" - that enhance the anti-tumor response to the experimental
drug candidate brosta... |
| | | Apr 14, 2009 | Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone| CTI to Request Priority Review
SEATTLE, April 14 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it began a rolling submission of a
New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for
pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma
(NHL). CTI expects to complete the submission this quarter and will request
priority review which if granted could lead to an approval decision fro... |
| | | Apr 13, 2009 | Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock| Company Further Simplifies Its Capital Structure By Completing the
Elimination of All Previously Outstanding Preferred Stock
SEATTLE, April 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) today announced that it has agreed to sell up to $20
million of Series 1 Preferred Stock and warrants in a registered offering to a
single institutional investor. The investor initially purchased today, for $15
million cash, shares of Series 1 Preferred Stock with a sta... |
| | | Apr 06, 2009 | CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture| SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it received $6.5 million from
Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the sale of its
50% interest in the Zevalin joint venture to Spectrum for approximately $16.5
million that closed in March 2009. CTI previously received approximately $6.5
million on March 2, 2009, related to this transaction, and the remaining $3.5
million, subject to adjustments ... |
| | | Apr 03, 2009 | Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market| SEATTLE, April 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that on April 2, 2009, CTI received
notice from The NASDAQ Stock Market ("NASDAQ") indicating that the company has
evidenced full compliance with all applicable requirements for continued
listing on The NASDAQ Capital Market. The notice followed CTI's compliance
with the minimum $35 million market value of listed securities requirement for
a minimum of ten consecutive tradin... |
| | | Mar 25, 2009 | Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders| SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of
Shareholders held on Tuesday, March 24, 2009.
At the meeting, shareholders approved the proposal to increase the number
of shares of authorized stock (including an increase in the number of shares
of authorized common stock), the proposal to increase the number of shares
available for issuance under its 2007 Equity Incentive Plan a... |
| | | Mar 24, 2009 | Cell Therapeutics, Inc. Special Meeting of Shareholders Scheduled for Tuesday, March 24, 2009| SEATTLE, March 24, 2009 /PRNewswire-FirstCall via COMTEX/ -- On Tuesday, March 24, 2009, at 6:00 PM Central European Time/1:00 PM Eastern Time/10:00 AM Pacific Time members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a Special Meeting of Shareholders at its Seattle headquarters located at 501 Elliott Ave. West, Seattle, WA 98119. The meeting will be webcast live on CTI's website at http://www.CellTherapeutics.com and archived for replay.
... |
| | | Mar 23, 2009 | Cell Therapeutics Announces Filing of Form 10-K| SEATTLE, March 23 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(NASDAQ and MTA: CTIC) today announced that it has filed its annual report on
Form 10-K for the year ended December 31, 2008. This filing is available for
review on CTI's website at www.CellTherapeutics.com, or on the Securities and
Exchange Commission's web site at www.sec.gov.
As required under NASDAQ Marketplace Rule 4350(b)(1)(B), CTI also
announced that its independent auditor's report included in the an... |
| | | Mar 19, 2009 | Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference| Company estimates sales of pixantrone, if approved, could potentially
reach $1 billion by 2014
SEATTLE, March 19 /PRNewswire-FirstCall/ -- Craig Philips, President of
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) reviewed CTI's programs
in a presentation at the 8th Annual WBBA Invest Northwest Conference on
Wednesday, March 18th . Mr. Philips' highlights focused on CTI's pixantrone
program for treatment of aggressive relapsed non-Hodgkin's lymphoma (NHL) and
OPAXIO for tre... |
| | | Mar 17, 2009 | Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest| SEATTLE, March 17 /PRNewswire-FirstCall/ -- Craig Philips, President of
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) will present at the 8th
Annual WBBA Invest Northwest Conference on Wednesday, March 18th at 10:10 AM
in the Harbor Dining Room of the Bell Harbor Conference Center.
Philips was named President of CTI in August of 2008. Prior to CTI,
Philips was Vice President and General Manager of Bayer Healthcare Oncology,
with direct responsibilities for all Development a... |
| | | Mar 16, 2009 | Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference| SEATTLE, March 16, /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management will present at the 8th Annual WBBA Invest
Northwest Conference on Wednesday, March 18th at 10:10 AM in the Harbor Dining
Room of the Bell Harbor Conference Center.
The presentation will also be webcast live with slides, and available for
replay after the presentation. The webcast can be accessed at
www.celltherapeutics.com.
WBBA Invest North... |
| | | Mar 16, 2009 | Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results| Net operating expenses decreased by 33% in 2008; Forecast cutting net
operating expenses by approximately 50% in 2009
CTI expects to complete pixantrone NDA submission in Q2 2009
SEATTLE, March 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today reported recent accomplishments and financial
results for the fourth quarter and year ended December 31, 2008.
Recent Events
Met primary endpoint in the Phase III study of pixantrone i... |
| | | Mar 12, 2009 | Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16| SEATTLE, March 12 /PRNewswire-FirstCall/ -- On Monday, March 16, 2009, at
8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific, members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will
host a conference call to discuss the Company's 2008 fourth quarter and
year-end achievements and financial results.
Conference Call Numbers
Monday, March 16
8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific Time
1-800-219-6110 (US ... |
| | | Mar 06, 2009 | Cell Therapeutics Announces Receipt of NASDAQ Listing Update| SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Company received a letter from
The NASDAQ Stock Market indicating that the NASDAQ Listing Qualifications
Panel has determined to continue the listing of the Company's common stock on
The NASDAQ Capital Market, subject to the condition that, on or before April
6, 2009, the Company demonstrate compliance with all applicable standards for
continued listing on The NASDA... |
| | | Feb 27, 2009 | CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center| SEATTLE, Feb. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has started a collective
dismissal procedure pursuant to Law 223/1991 concerning its Bresso, Italy,
(CTE) employees. The collective dismissal will involve a total of 62
employees. Within 75 days of the consultation procedure, the company, in
cooperation with the Trade Unions, will review solutions that may reduce the
social impact of the decision.
CTI is moving... |
| | | Feb 27, 2009 | Cell Therapeutics Reschedules Special Meeting| SEATTLE, Feb. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has rescheduled the special
meeting of shareholders from Friday, February 27, 2009 to Tuesday, March 24,
2009, in order to allow additional time for the proxy materials, first mailed
to shareholders by CTI on or about February 12, 2009, to be adequately
disseminated and reviewed by CTI shareholders and so that all shareholders
receive at least 20 days written notice o... |
| | | Feb 20, 2009 | Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million| CTI to focus on Pixantrone and OPAXIO Approval and Commercialization
SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it exercised its option to sell
its 50% ownership interest in the Zevalin joint venture to Spectrum
Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established
a joint venture in December 2008 to develop and commercialize Zevalin. At that
time CTI contributed all of the Zevalin re... |
| | | Feb 18, 2009 | Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma| Phase III safety data underscores clinical benefit of pixantrone
SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data
from the phase III trial of pixantrone provides further support for a robust
clinical benefit for pixantrone when used as single agent therapy in the
treatment of multiple relapsed aggressive non-Hodgkin's lymphoma (NHL). On an
intent-to-treat analysis, pixantrone recipient... |
| | | Feb 17, 2009 | Cell Therapeutics to Resume Trading on MTA and NASDAQ| SEATTLE, Feb 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective wi... |
| | | Feb 11, 2009 | Cell Therapeutics Updates Shareholders on Trading| SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) announced today that the Borsa Italiana, which is the
entity that governs the trading of the Company's common stock on the MTA stock
market in Milan, Italy, suddenly suspended trading of the Company's shares in
Italy on February 10th. As a result of the suspension of trading by the Borsa
Italiana, the security has additionally been halted on the NASDAQ Stock Market
pursuant to Marketplace Rule 41... |
| | | Feb 10, 2009 | Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone| SEATTLE, Feb 10, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009.
... |
| | | Feb 09, 2009 | Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast| SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management's presentation at the 11th Annual BIO CEO &
Investor Conference on Tuesday, February 10th at 9:30 AM Eastern will be
webcast live with slides at http://www.celltherapeutics.com.
The presentation will take place in the Jade Room at the Waldorf-Astoria
Hotel, and will also be available for replay after the presentation.
BIO CEO & Investor Conference
... |
| | | Feb 06, 2009 | CTI Seeks Strategic Alternative for Italian Facility| Spin-off would reduce CTI burn rate by $14 million
SEATTLE, Feb. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has engaged the services of a
strategic advisory consulting firm, Adjuvant Global Advisors, LLC, (Adjuvant)
to assist in developing strategic options for a partnership, asset divestment
or joint venture for Cell Therapeutics Europe Sede Secondaria (CTE), the
preclinical drug development arm of CTI, in Bresso, Milan... |
| | | Feb 05, 2009 | Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share| SEATTLE, Feb 05, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics (CTI)
(Nasdaq and MTA: CTIC) announced today that it has issued 6,634 shares of
Series F Preferred Stock in exchange for 6,634 shares of CTI's Series A, B and
C Convertible Preferred Stock. The exchange constitutes 83% in interest of all
series of CTI's Convertible Preferred Stock. Each share of the new Preferred
Stock will become convertible into 7,143 shares of CTI's common stock, at a
conversion price of $0.14 ... |
| | | Jan 28, 2009 | Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial| SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI)
(Nasdaq and MTA: CTIC) announced today preliminary progression-free survival
(PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone
that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma
(NHL) treated with pixantrone experienced a statistically significant
improvement in median progression-free survival, compared with other
single-agent chemotherapeutic agents (4.7 months vs.... |
| | | Jan 27, 2009 | Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission| SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI)
(Nasdaq and MTA: CTIC) announced today that after communication with the Food
and Drug Administration (FDA), CTI expects to begin submission of a rolling
New Drug Application (NDA) and request priority review for pixantrone to treat
relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009.
If granted priority review a decision on the NDA could occur before the end of
2009.
"This communication f... |
| | | Jan 26, 2009 | Cell Therapeutics Receives Additional NASDAQ Notification| SEATTLE, Jan. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Company received an Additional
Staff Determination letter (the "Determination Letter") from the Listing
Qualifications Staff (the "Staff") of The NASDAQ Stock Market indicating that
the Company did not comply with Marketplace Rule 4350(i)(1)(C) when the
Company amended the acquisition agreement with Systems Medicine, Inc. ("SMI")
and issued additional common shares t... |
| | | Jan 26, 2009 | Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference| SEATTLE, Jan. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management will present at the 11th Annual BIO CEO &
Investor Conference on Tuesday, February 10th at 9:30 AM in the Jade Room of
the Waldorf-Astoria Hotel.
The presentation will also be webcast live with slides, and available for
replay after the presentation. The webcast can be accessed at
http://www.celltherapeutics.com.
BIO CEO & Investor Conference
... |
| | | Jan 24, 2009 | Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders| SEATTLE, Jan. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI)
(Nasdaq and MTA: CTIC) announced today that the Company will now hold a
Special Meeting of Shareholders on February 27, 2009 in lieu of the Special
Meeting of Shareholders that was scheduled to take place on February 6, 2009.
Shareholders of record at the close of business on February 4, 2009, the
record date established by the Board of Directors, will be entitled to vote at
the Special Meeting. Updated proxy materials,... |
| | | Jan 22, 2009 | Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma| SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today results of a study published by
Esmaeli, et al. online on January 15, 2009 in the Annals of Oncology
demonstrating that rituximab followed by single agent Zevalin (ibritumomab
tiuxetan) in a front-line setting for patients with MALT lymphoma and low-
grade follicular lymphoma that primarily involved the conjunctiva or orbit
produced a complete response rate of 83 percent.
... |
| | | Jan 14, 2009 | Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009| Projects lower burn rate for 2009 targeting cashflow break-even by Q4-2009
SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association
with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics,
Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008
accomplishments. CTI is seeking to obtain two new drug approvals in 2009 in
addition to potential label expansion for Zevalin(R). In November CTI
established a 50/50 joint venture wit... |
| | | Jan 08, 2009 | Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals|
SEATTLE, Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that they received $7.5 million pursuant to the joint venture transaction with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. In December, the Company received the initial $7.5 million payment in connection with the closing of such transaction. The Company may earn up to an additional $15 million in product s... |
| | | Jan 07, 2009 | Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market| SEATTLE, Jan. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has received notification that
the NASDAQ Listing Qualifications Panel has granted CTI's request to transfer
the listing of its common stock from The NASDAQ Global Market to The NASDAQ
Capital Market, which will be effective with the open of trading on Thursday,
January 8, 2009. CTI's shares will continue to trade under the ticker symbol
CTIC.
CTI's continued list... |
| | | Dec 16, 2008 | Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US| SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI)
(Nasdaq and MTA: CTIC) announced today they have closed the transaction with
Spectrum Pharmaceuticals, Inc. to form a 50/50 owned joint venture, RIT
Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumomab
tiuxetan) in the United States. In connection with the closing, Cell
Therapeutics received an initial payment of $7.5 million and will receive an
additional $7.5 million in early January. ... |
| | | Dec 09, 2008 | Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma| SEATTLE, Dec. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) announced today that the results of three Italian
multicenter studies utilizing Zevalin(R) ([90Y]-ibritumomab tiuxetan) were
presented at the American Society of Hematology (ASH) 50th Annual Meeting in
San Francisco, CA.
In one presentation, the Italian Cooperative Study Group in a phase II
study investigated the use of single dose Zevalin as sole initial treatment in
15 patients with advanced... |
| | | Dec 08, 2008 | Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months| Updated Phase III First-line Indolent Trial (FIT) Results Confirms Continued Significant Benefit over Chemotherapy Alone
SEATTLE, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that extended follow-up data for the
Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study
presented at the American Society of Hematology (ASH) 50th Annual Meeting by
Morschhauser, et al demonstrated the contin... |
| | | Dec 05, 2008 | Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes| SEATTLE, Dec 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq and MTA: CTIC) today announced that that its Board
of Directors has authorized a "Modified Dutch Auction" tender offer to
purchase a portion or all of five series of Convertible Notes (the "Notes") as
follows:
4% Convertible Senior Subordinated Notes due 2010
5.75% Convertible Senior Notes due 2011
6.75% Convertible Senior Notes due 2010
7.5% Convertible Seni... |
| | | Dec 05, 2008 | Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes| Retires $30 Million of Previously Issued Convertible Notes
SEATTLE, Dec. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq and MTA: CTIC) today announced that a single
institutional investor shall purchase, for $32.65 million, newly issued 10%
Convertible Senior Notes due 2011 (the "Notes"), with a conversion price of
$0.137 per share.
The new Notes would have a $32.65 million initial principal balance and
feature a make-whole provision... |
| | | Dec 04, 2008 | Zevalin Data to be Presented at ASH 2008| 12 presentations and posters on ZEVALIN(R) in Non-Hodgkin's Lymphoma scheduled
SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced presentations or posters of interest
related to Zevalin(R) (ibritumomab tiuxetan) to be presented at the 50th
Annual Meeting of the American Society of Hematology (ASH), December 5-9, 2008
in San Francisco.
In addition, James Bianco, M.D., CEO of Cell Therapeutics will participate
in a panel ho... |
| | | Dec 01, 2008 | FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review| May Accelerate First-line Launch by Four Months
SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug
Administration (FDA) has accepted for filing and review, and has granted
priority review status for, the supplemental Biologics License Application
(sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation
therapy for patients with follicular B-cell non-Hodgkin's lymphom... |
| | | Dec 01, 2008 | Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides| SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, Cell
Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a
conference call to discuss the agreement with Spectrum Pharmaceuticals of
Irvine, California to jointly market and develop Zevalin(R). The call will be
webcast with slides, and the slides are also available for review on CTI's
website, http://www.celltherapeutics.com/... |
| | | Nov 28, 2008 | Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals| SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will
host a conference call to discuss the agreement with Spectrum Pharmaceuticals
of Irvine, California to jointly market and develop Zevalin(R).
Conference Call Numbers
Monday, December 1
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific T... |
| | | Nov 26, 2008 | Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug| - ZEVALIN is Currently FDA Approved for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma - sBLA for First Line Consolidation Therapy Is Currently Under Review By The FDA - Complements Existing and Potential Oncology Product Portfolios of Both Companies
IRVINE, Calif., and SEATTLE, Nov 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Spectrum
Pharmaceuticals, Inc. (Nasdaq: SPPI) and Cell Therapeutics, Inc.
(Nasdaq: CTIC)(MTA: CTIC) announced today they have entered into an agre... |
| | | Nov 11, 2008 | Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint| Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher
Compared to Standard Chemotherapy
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy
endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for
patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based
on a preliminary intent to treat efficacy analysis. ... |
| | | Nov 10, 2008 | Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma|
SEATTLE, Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has
published in the November 1, 2008 issue the results of a study authored by
Samual Jacobs et al. investigating the use of short-course CHOP-R followed by
Zevalin ([90Y]-ibritumomab tiuxetan) and extended rituximab as first-line
treatment in follicular non-Hodgkin's lymphoma patients. Addition of the
Zevalin therapeu... |
| |
|
